Fatih Kahraman

Dr. Fatih Kahraman

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in International Journal of Cardiology
Verified
Journal Article
Closed access
FKFatih Kahraman
Fatih Kahraman
AYAhmet Seyda Yılmaz
Ahmet Seyda Yılmaz
IEİbRahim Ersoy
İbRahim Ersoy
MDMevlüt Demir
Mevlüt Demir
HOHikmet Orhan
Hikmet Orhan

13 October 2023 in Medicine
Verified
Journal Article
Open access
MDMevlut Demir
Mevlut Demir
FKFatih Kahraman
Fatih Kahraman
TSTaner Sen
Taner Sen
MAMehmet Ali Astarcioglu
Mehmet Ali Astarcioglu
Acute coronary syndrome (ACS) is an urgent clinical condition of cardiovascular diseases. The present study evaluated the predictive efficacy of the hemoglobin to serum creatinine ratio (Hgb/Cr) on long-term mortality in patients with ACS. The ratio, representing the proportion of the 2 values, is cheap, practical, and very easy to calculate at the bedside. Our study included 475 patients who were admitted to the coronary intensive care unit with a diagnosis of ACS and who underwent coronary angiography. The Hgb/Cr ratio was calculated by dividing the admission hemoglobin by the admission serum creatinine. All patient data were collected from the electronic hospital information system, patient files, and the hospital’s archive. A comparison of the patients laboratory findings revealed that the Hgb/Cr ratios differed significantly between the survivor and non-survivor group [16.6 (7.7–49) vs 13.8 (4.91–32.8), respectively; P < .001]. A univariate Cox regression analysis showed that the Hgb/Cr ratio was statistically significant in predicting long-term mortality (0.836; 95% confidence interval [CI]: 0.781–0.895; P < .001). After adjusting the model by adding clinically and statistically significant variables, the Hgb/Cr ratio was still an independent predictor of long-term mortality (0.886; 95% CI: 0.815–0.963; P = .004). The Hgb/Cr ratio’s discriminant ability was tested with an receiver operating characteristic curve analysis. The Hgb/Cr ratio’s area under the curve value was 0.679 (95% CI: 0.609–0.750; P < .001). A survival analysis using the Kaplan–Meier curve of the 2 Hgb/Cr ratio groups (according to cutoff value) revealed that the low-Hgb/Cr group had a significantly higher mortality rate than high-Hgb/Cr group. The Hgb/Cr ratio was found to be an independent predictor of long-term mortality in ACS patients.

11 March 2024 in Future Cardiology
Verified
Journal Article
Closed access
YYYunus emre Yavuz
Yunus emre Yavuz
FKFatih Kahraman
Fatih Kahraman
Aim: Evaluation of the performance of ChatGPT-4.0 in providing prediagnosis and treatment plans for cardiac clinical cases by expert cardiologists. Methods: 20 cardiology clinical cases developed by experienced cardiologists were divided into two groups according to preparation methods. Cases were reviewed and analyzed by the ChatGPT-4.0 program, and analyses of ChatGPT were then sent to cardiologists. Eighteen expert cardiologists evaluated the quality of ChatGPT-4.0 responses using Likert and Global quality scales. Results: Physicians rated case difficulty (median 2.00), revealing high ChatGPT-4.0 agreement to differential diagnoses (median 5.00). Management plans received a median score of 4, indicating good quality. Regardless of the difficulty of the cases, ChatGPT-4.0 showed similar performance in differential diagnosis (p: 0.256) and treatment plans (p: 0.951). Conclusion: ChatGPT-4.0 excels at delivering accurate management and demonstrates its potential as a valuable clinical decision support tool in cardiology.

1 January 2019 in Brazilian Journal of Cardiovascular Surgery
Verified
Journal Article
Open access
FAFatih Aksoy
Fatih Aksoy
SGSerdar Guler
Serdar Guler
FKFatih Kahraman
Fatih Kahraman
MKMevlüt Serdar Kuyumcu
Mevlüt Serdar Kuyumcu
ABAli Bağcı
Ali Bağcı
EVErcan Varol
Ercan Varol
Metabolic syndrome (MetS) is defined as an association between diabetes, hypertension, obesity and dyslipidemia and an increased risk of cardiovascular disease. Mitral annular calcification (MAC) is associated with several cardiovascular disorders, including coronary artery disease, atrial fibrillation (AF), heart failure, ischemic stroke and increased mortality. The CHA2DS2-VASc score is used to estimate thromboembolic risk in AF. However, the association among MAC, MetS and thromboembolic risk is unknown and was evaluated in the current study. The study group consisted of 94 patients with MAC and 86 patients with MetS. Patients were divided into two groups: those with and those without MAC. Patients with MAC had a higher MetS rate (P<0.001). In patients with MAC, the CHA2DS2-VASc scores and the rate of cerebrovascular accident and AF were significantly higher compared to those without MAC (P<0.001, for both parameters). The results of the multivariate regression analysis showed that history of smoking, presence of MetS and high CHA2DS2-VASc scores were associated with the development of MAC. ROC curve analyses showed that CHA2DS2-VASc scores were significant predictors for MAC (C-statistic: 0.78; 95% CI: 0.706-0.855, P<0.001). Correlation analysis indicated that MAC was positively correlated with the presence of MetS and CHA2DS2-VASc score (P=0.001, r=0.264; P<0.001, r=0.490). We have shown that CHA2DS2-VASc score and presence of MetS rates were significantly higher in patients with MAC compared without MAC. Presence of MAC was correlated with CHA2DS2-VASc score, presence of MetS, AF and left atrial diameter and negatively correlated with left ventricular ejection fraction.

1 January 2024 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
TŞTaner Şen
Taner Şen
LALale Dinç Asarcıklı
Lale Dinç Asarcıklı
SGSaadet Güven
Saadet Güven
UKUmut Kocabaş
Umut Kocabaş
MÖMehmet Özgeyik
Mehmet Özgeyik
ATAbdullah Tuncez
Abdullah Tuncez
The aim of this study was to assess the adherence to the current European Society of Cardiology dyslipidemia guidelines, the ratio of reaching target values according to risk groups, and the reasons for not reaching LDL-cholesterol (LDL-C) goals in patients on already statin therapy in a cardiology outpatient population. The AIZANOI study is a multi-center, cross-sectional observational study including conducted in 9 cardiology centers between August 1, 2021, and November 1, 2021. A total of 1225 patients (mean age 62 ± 11 years, 366 female) who were already on statin therapy for at least 3 months were included. More than half (58.2%) of the patients were using high-intensity statin regimens. Only 26.2% of patients had target LDL-C level according to their risk score. Despite 58.4% of very high-risk patients and 44.4% of high-risk patients have been using a high-intensity statin regimen, only 24.5% of very-high-risk patients and only 34.9% of high-risk patients have reached guideline-recommended LDL-C levels. Most prevalent reason for not using target dose statin was physician preference (physician inertia) (40.3%). The AIZANOI study showed that we achieved a target LDL-C level in only 26.2% of patients using statin therapy. Although 58.4% of patients with a very high SCORE risk and 44.4% of patients with a high SCORE risk were using a target dose statin regimen, we were only able to achieve guideline-recommended LDL-C levels in 24.5% and 34.9% of them, respectively, in cardiology outpatients clinics. Physician inertia is one of the major factors in non-adherence to guidelines. These findings highlight that combination therapy is needed in most of the patients.

30 September 2022 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
FKFatih Kahraman
Fatih Kahraman
AYAhmet Seyda Yilmaz
Ahmet Seyda Yilmaz
MDMevlüt Demir
Mevlüt Demir
FBFatih Beşiroğlu
Fatih Beşiroğlu
Aim This study evaluated the prognostic ability of the APACHE II score and compared it with inflammatory indices in patients with acute coronary syndrome (ACS). Material and Methods A total of 525 patients with ACS were retrospectively enrolled in the study. APACHE II scores were calculated and C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), and systemic immune-inflammatory index (SII) were recorded. The APACHE II score was compared with inflammatory indices for predicting in-hospital mortality. Results Univariate logistic regression (LR) analysis showed that CRP, SII, NLR, ejection fraction, chronic kidney disease, gender, and APACHE II score were significant predictors of mortality. In multiple LR analysis, the APACHE II score was found to be a solitary, significant predictor of in-hospital mortality (OR: 1.201, 95 % CI: 1.122–1.285; p<0.001). In the Receiver Operating Characteristics curve, using a cut-off point of 16.5, the APACHE II score predicted in-hospital mortality with 70.4 % sensitivity and 92.9 % specificity. Conclusion The APACHE II score may be used as a predictor of in-hospital mortality better than inflammatory markers in ACS patients.